Iranian Red Crescent Medical Journal

Published by: Kowsar

MS14, a Marine Herbal Medicine, an Immunosuppressive Drug in Experimental Autoimmune Encephalomyelitis

Abbas Ebrahimi Kalan 1 , 2 , Jafar Soleimani Rad 1 , Laya Kafami 2 , 3 , Daryoush Mohamadnezhad 1 , Amir Afshin Khaki 1 and Amaneh Mohammadi Roushandeh 1 , 4 , *
Authors Information
1 Anatomical Sciences Department, School of Medicine, Tabriz University of Medical Sciences, Tabriz, IR Iran
2 Shefa Neuroscience Research Center, Tehran, IR Iran
3 Pathobiology Department, School of Medicine, Alborz University of Medical Sciences, Karaj, IR Iran
4 Anatomical Sciences Department, School of Medicine, Hamedan University of Medical Sciences, Hamedan, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: July 5, 2014, 16 (7); e16956
  • Published Online: July 5, 2014
  • Article Type: Research Article
  • Received: December 16, 2013
  • Revised: February 2, 2014
  • Accepted: February 22, 2014
  • DOI: 10.5812/ircmj.16956

To Cite: Ebrahimi Kalan A, Soleimani Rad J, Kafami L, Mohamadnezhad D, Khaki A A, et al. MS14, a Marine Herbal Medicine, an Immunosuppressive Drug in Experimental Autoimmune Encephalomyelitis, Iran Red Crescent Med J. 2014 ; 16(7):e16956. doi: 10.5812/ircmj.16956.

Abstract
Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Chen YC, Yang X, Miao L, Liu ZG, Li W, Zhao ZX, et al. Serum level of interleukin-6 in Chinese patients with multiple sclerosis. J Neuroimmunol. 2012; 249(1-2): 109-11[DOI][PubMed]
  • 2. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol. 2006; 60(1): 12-21[DOI][PubMed]
  • 3. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol. 2002; 15(3): 227-31[PubMed]
  • 4. Zozulya AL, Wiendl H. The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. Hum Immunol. 2008; 69(11): 797-804[DOI][PubMed]
  • 5. Rodgers JM, Miller SD. Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J Biol Med. 2012; 85(4): 447-68[PubMed]
  • 6. Kafami L, Etesami I, Felfeli M, Enayati N, Ghiaghi R, Aminian A, et al. Methadone diminishes neuroinflammation and disease severity in EAE through modulating T cell function. J Neuroimmunol. 2013; 255(1-2): 39-44[DOI][PubMed]
  • 7. Nessler S, Bruck W. Advances in multiple sclerosis research in 2009. J Neurol. 2010; 257(9): 1590-3[DOI][PubMed]
  • 8. Wei W, Du C, Lv J, Zhao G, Li Z, Wu Z, et al. Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation. J Immunol. 2013; 190(1): 138-46[DOI][PubMed]
  • 9. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986; 324(6092): 73-6[DOI][PubMed]
  • 10. Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer. 2000; 88(9): 2061-71[PubMed]
  • 11. Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol. 1994; 9(5): 462-7[PubMed]
  • 12. Kitajima T, Tajima Y, Kuroki T, Tsuneoka N, Adachi T, Kanematsu T. Interleukin-6 expression on the biliary epithelia during inflammation-associated biliary carcinogenesis in bilioenterostomized hamsters. J Surg Res. 2010; 162(1): 54-8[DOI][PubMed]
  • 13. Van Wagoner NJ, Benveniste EN. Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol. 1999; 100(1-2): 124-39[PubMed]
  • 14. Schonrock LM, Gawlowski G, Bruck W. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci Lett. 2000; 294(1): 45-8[PubMed]
  • 15. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol. 2004; 251(3): 261-8[DOI][PubMed]
  • 16. Roya Y, Nayere A, Naseri M. The Effect of MS14 on Production of Pro-inflammatory Cytokines by Macrophages. Iran J Basic Med Sci. 2011; 14(1): 89-93
  • 17. Naseri M, Ahmadi A, Gharahgouzli K, Nabavi M , Faghihzadeh S , Ashtarian N . Clinical and toxicological evaluation of MS14 natural product in patients with multiple sclerosis. Daneshvar Med. 2007; 14(68): 64-59
  • 18. Ahmadi A, Habibi G, Farrokhnia M. MS14, an Iranian herbal-marine compound for the treatment of multiple sclerosis. Chin J Integr Med. 2010; 16(3): 270-1[DOI][PubMed]
  • 19. Tafreshi AP, Ahmadi A, Ghaffarpur M, Mostafavi H, Rezaeizadeh H, Minaie B, et al. An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis. Phytother Res. 2008; 22(8): 1083-6[DOI][PubMed]
  • 20. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, Hooshmand F, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol. 2007; 4(1): 50-7[PubMed]
  • 21. Furrie E, Macfarlane S, Thomson G, Macfarlane GT, Gut Biology G, et al. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology. 2005; 115(4): 565-74[DOI][PubMed]
  • 22. Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc. 2006; 1(4): 1810-9[DOI][PubMed]
  • 23. Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest. 2002; 110(4): 493-7[DOI][PubMed]
  • 24. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012; 8(9): 1254-66[DOI][PubMed]
  • 25. Uzawa A, Mori M, Kuwabara S. Neuromyelitis optica: concept, immunology and treatment. J Clin Neurosci. 2014; 21(1): 12-21[DOI][PubMed]
  • 26. Leech MD, Barr TA, Turner DG, Brown S, O'Connor RA, Gray D, et al. Cutting edge: IL-6-dependent autoimmune disease: dendritic cells as a sufficient, but transient, source. J Immunol. 2013; 190(3): 881-5[DOI][PubMed]
  • 27. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007; 8(9): 967-74[DOI][PubMed]
  • 28. Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther. 2009; 13(4): 225-44[DOI][PubMed]
  • 29. Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol. 2004; 173(9): 5794-800[PubMed]
  • 30. Yaraee R, Ghazanfari T, Eghtedardoost M, Rajabi M, Naseri M. The effect of MS14 on innate and cellular immune responses in BALB/c mice. Immunopharmacol Immunotoxicol. 2011; 33(3): 509-14[DOI][PubMed]
  • 31. Etemadifar M, Sayahi F, Abtahi SH, Shemshaki H, Dorooshi GA, Goodarzi M, et al. Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study. Int J Neurosci. 2013; 123(7): 480-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments